Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)

NCT03149575 is registered in ClinicalTrials.gov with DelMar Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03149575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03149575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)
Lead sponsor
DelMar Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
October 27, 2017
Completion date
August 31, 2019
Enrollment
2 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, gbm, glioblastoma, glioblastoma multiforme, glioma